Entity

Time filter

Source Type


Aomatsu N.,Imazato Gastroenteric Hospital | Doi Y.,Imazato Gastroenteric Hospital | Takemura S.,Imazato Gastroenteric Hospital | Yui S.,Imazato Gastroenteric Hospital
Japanese Journal of Cancer and Chemotherapy | Year: 2014

An 83-year-old woman was admitted to our hospital because of general fatigue and symptoms of anemia. For 20 years, she had experienced right hypochondrial pain several times a year. Colonoscopic examination revealed a type 2 tumor at the ascending colon. The biopsy specimen was a Group 5 and type 0-IIa polyp at the transverse colon. The endoscopic mucosal resection (EMR) specimen was a well-differentiated adenocarcinoma (Stage pSM [2 mm], ly0, v0). An apple core lesion in the cecum was detected by enema. Abdominal computed tomography demonstrated cholecystolithiasis and no metastasis or distant metastases. Therefore, a diagnosis of multifocal colon carcinoma and cholecystolithiasis was made. Expanding right hemicolectomy with cholecystectomy was performed. The patient was discharged without any complications. Subsequently, she underwent adjuvant chemotherapy for 6 months. At present, 1 year after surgery, the patient is still alive and has shown no signs of recurrence. Source


Aomatsu N.,Imazato Gastroenteric Hospital | Doi Y.,Imazato Gastroenteric Hospital | Takemura S.,Imazato Gastroenteric Hospital | Tanaka H.,Osaka City University | And 3 more authors.
Japanese Journal of Cancer and Chemotherapy | Year: 2014

We observed a case of unresectable Stage IV human epidermal growth factor receptor 2 (HER2) -positive advanced gastric cancer treated by using trastuzumab combined with chemotherapy. A 55-year-old man was admitted to our hospital because of dysphagia for 4 months. He was diagnosed with advanced gastric cancer with pyloric stenosis, multiple lung metastases, multiple liver metastases, peritoneal dissemination, and rectal muscle invasion. First, we initiated weekly chemotherapy with paclitaxel. Because the biopsy tissue was HER2-positive, we added trastuzumab to the weekly paclitaxel regimen. After 2 courses, dietary intake became possible, and he was then discharged from our hospital. However, after 3 courses of chemo-therapy, disease progression was observed. He was admitted to the hospital again. We inserted a duodenal stent and changed the chemotherapy regimen to fluorouracil plus cisplatin (CDDP) plus trastuzumab. He did not experience any major adverse events during treatment. However, after 2 courses of chemotherapy, he died owing to cancerous peritonitis and intestinal obstruction. Source

Discover hidden collaborations